Showing results (1-10 of 327) with videos related to
Sort By:
Pageof 33
Laboratory Investigation; a Journal of Technical Methods and Pathology|January 12, 2016
Canonical Wnt signaling in systemic sclerosisChristina Bergmann, Jörg H W DistlerAnnals of the Rheumatic Diseases|February 18, 2017
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophagesChristiane Maier, Andreas Ramming, Christina Bergmann, et al.Current Rheumatology Reports|January 8, 2013
Morphogen pathways in systemic sclerosisChristian Beyer, Jörg H W DistlerExperimental Dermatology|October 15, 2013
Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?Clara Dees, Jörg H W DistlerTherapeutic Advances in Musculoskeletal Disease|August 15, 2022
A broad look into the future of systemic sclerosisGabriela Riemekasten, Jörg H W DistlerBiochimica Et Biophysica Acta|June 26, 2012
Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human diseaseChristian Beyer, Jörg H W DistlerArthritis & Rheumatology (Hoboken, N.J.)|November 22, 2021
Impaired Mitochondrial Transcription Factor A Expression Promotes Mitochondrial Damage to Drive Fibroblast Activation and Fibrosis in Systemic SclerosisXiang Zhou, Thuong Trinh-Minh, Cuong Tran-Manh, et al.Arthritis Research & Therapy|July 7, 2010
Vascular alterations upon activation of TGFbeta signaling in fibroblasts--implications for systemic sclerosisAngelika Horn, Jörg H W DistlerAnnals of the Rheumatic Diseases|August 30, 2011
Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathwayChristina Bergmann, Alfiya Akhmetshina, Clara Dees, et al.Pharmacological Research|July 19, 2015
From pathogenesis to therapy--Perspective on treatment strategies in fibrotic diseasesAndreas Ramming, Clara Dees, Jörg H W DistlerPageof 33